alpha 1-Antitrypsin

• 

  Subject Areas on Research

  • A novel function of VCP (valosin-containing protein; p97) in the control of N-glycosylation of proteins in the endoplasmic reticulum. 
  • Aerosol alpha 1-antitrypsin treatment for cystic fibrosis. 
  • Age and functional correlations of markers of coagulation and inflammation in the elderly: functional implications of elevated crosslinked fibrin degradation products (D-dimers). 
  • Alpha 1-antitrypsin deficiency and pregnancy. 
  • Alpha-1-antitrypsin globules in hepatocytes of elderly persons with liver disease. 
  • Alpha-1-antitrypsin types in five Chinese national minorities. 
  • Alpha₁-antitrypsin deficiency-related alleles Z and S and the risk of Wegener's granulomatosis. 
  • Analysis of the plasma elimination kinetics and conformational stabilities of native, proteinase-complexed, and reactive site cleaved serpins: comparison of alpha 1-proteinase inhibitor, alpha 1-antichymotrypsin, antithrombin III, alpha 2-antiplasmin, angiotensinogen, and ovalbumin. 
  • Anti-inflammatory effects of pentoxifylline in claudication. 
  • Biomarkers to help guide management of patients with pulmonary nodules. 
  • Causal Pathways from Enteropathogens to Environmental Enteropathy: Findings from the MAL-ED Birth Cohort Study. 
  • Danazol-induced augmentation of serum alpha 1-antitrypsin levels in individuals with marked deficiency of this antiprotease. 
  • Danazol-induced elevation of serum alpha 1-antitrypsin in individuals with severe deficiency of this antiprotease. 
  • Deficiency of α-1-antitrypsin influences systemic iron homeostasis. 
  • Editing out five Serpina1 paralogs to create a mouse model of genetic emphysema. 
  • Effect of parturition on serum alpha 1-antiprotease (alpha 1-antitrypsin) 
  • Elevation of intact and proteolytic fragments of acute phase proteins constitutes the earliest systemic antiviral response in HIV-1 infection. 
  • Evaluation of the rapid plasma elimination of recombinant alpha 1-proteinase inhibitor: synthesis of polyethylene glycol conjugates with improved therapeutic potential. 
  • Geographical variability of alpha-1-antitrypsin alleles in China: a study on six Chinese populations. 
  • Hepatocyte uptake of alpha 1-proteinase inhibitor-trypsin complexes in vitro: evidence for a shared uptake mechanism for proteinase complexes of alpha 1-proteinase inhibitor and antithrombin III. 
  • Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis. 
  • In vivo catabolism of alpha 1-antichymotrypsin is mediated by the Serpin receptor which binds alpha 1-proteinase inhibitor, antithrombin III and heparin cofactor II. 
  • In vivo catabolism of alpha 1-proteinase inhibitor-trypsin, antithrombin III-thrombin and alpha 2-macroglobulin-methylamine. 
  • In vivo catabolism of heparin cofactor II and its complex with thrombin: evidence for a common receptor-mediated clearance pathway for three serine proteinase inhibitors. 
  • In vivo metabolism of inter-alpha-trypsin inhibitor and its proteinase complexes: evidence for proteinase transfer to alpha 2-macroglobulin and alpha 1-proteinase inhibitor. 
  • Kinetics and physiologic relevance of the inactivation of alpha 1-proteinase inhibitor, alpha 1-antichymotrypsin, and antithrombin III by matrix metalloproteinases-1 (tissue collagenase), -2 (72-kDa gelatinase/type IV collagenase), and -3 (stromelysin). 
  • Methionine sulfoxide and the oxidative regulation of plasma proteinase inhibitors. 
  • Peripheral blood gene expression of acute phase proteins in people with first episode psychosis. 
  • Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins. 
  • Polyethylene glycol modification of serpins improves therapeutic potential. 
  • Reactive Center Loop Insertion in α-1-Antitrypsin Captured by Accelerated Molecular Dynamics Simulation. 
  • Regulation of factor IXa in vitro in human and mouse plasma and in vivo in the mouse. Role of the endothelium and the plasma proteinase inhibitors. 
  • Secretory leukocyte proteinase inhibitor is preferentially increased in patients with acute respiratory distress syndrome. 
  • Selectivity and stereospecificity of the reactions of dichlorodiammineplatinum(II) with three purified plasma proteins. 
  • Smoking and disease: effect on serum antitrypsin in hospitalized patients. 
  • Strategies for dissecting genetic-environmental interactions in neurodegenerative disorders. 
  • Stromelysin-3 is overexpressed by stromal elements in primary non-small cell lung cancers and regulated by retinoic acid in pulmonary fibroblasts. 
  • Synergistic effects of exposure to concentrated ambient fine pollution particles and nitrogen dioxide in humans. 
  • The effect of phosphatidylserine on the inhibition of human factor Xa by the plasma proteinase inhibitors. 
  • The macrophage-mediated regulation of hepatocyte synthesis of antithrombin III and alpha 1-proteinase inhibitor. 
  • Tumor necrosis factor, natural killer activity and other measures of immune function and inflammation in elderly men with heart failure. 
  • cis-dichlorodiammineplatinum (II) as a selective modifier of the oxidation-sensitive reactive-center methionine in alpha 1-antitrypsin.